TipHub

118.57

-0.38 -0.32%

As of 28 Jul 2026 · delayed

NSE Listed · Healthcare

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-06-17
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

Lotus Eye Hospital & Institute Ltd. (LOTUSEYE)

Volume: 9,290Avg Vol 1W: 36,471Avg Vol 1M: 28,21452W Range:70.84147
Market Cap
Current Price₹118.57
Previous Close₹118.95
High / Low (52w)₹147 / ₹70.84
Volume9,290
Avg Vol (1W)36,471
Avg Vol (1M)28,214
Stock P/E194.17
Book Value₹28.91
Dividend Yield
ROE
ROA
Revenue (TTM)₹54 Cr
Revenue Growth
Profit Margin
Total Debt
Shares Outstanding
Face Value₹10
EPS (TTM)₹-0.15
P/B4.1
Debt / Equity
50 DMA₹120.31
200 DMA₹116.57
Day change-0.32%
SurveillanceLT-ASM · ASM 1
Price Chart
118.57 60.58% · 1Y
1416912.7L
2025-07-29
2026-07-28

20-day avg volume: 30K shares

Cons
  • Stock trades at a high P/E of 194.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹13 Cr₹13 Cr₹12 Cr₹12 Cr₹14 Cr₹13 Cr₹14 Cr₹14 Cr
EBITDA₹1 Cr₹0 Cr₹0 Cr₹1 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr
EPS
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹39 Cr₹39 Cr₹41 Cr₹33 Cr₹40 Cr₹48 Cr₹50 Cr₹51 Cr
EBITDA₹2 Cr₹1 Cr₹2 Cr₹2 Cr₹4 Cr₹6 Cr₹4 Cr₹2 Cr
Net Profit₹2 Cr₹1 Cr₹1 Cr₹2 Cr₹3 Cr₹4 Cr₹3 Cr₹1 Cr
EPS0.840.340.510.751.441.961.40.36
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹57 Cr₹58 Cr₹59 Cr₹62 Cr₹63 Cr₹67 Cr₹70 Cr₹83 Cr
Total Liabilities₹6 Cr₹7 Cr₹7 Cr₹7 Cr₹6 Cr₹7 Cr₹10 Cr₹22 Cr
Equity₹50 Cr₹51 Cr₹53 Cr₹55 Cr₹58 Cr₹59 Cr₹60 Cr₹60 Cr
Total Debt₹16 Cr
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹3 Cr₹5 Cr₹6 Cr₹7 Cr₹3 Cr₹3 Cr
Investing₹0 Cr₹-4 Cr₹-2 Cr₹-4 Cr₹-4 Cr₹-12 Cr
Financing₹0 Cr₹-2 Cr₹-2 Cr₹-3 Cr₹-2 Cr₹9 Cr
Free Cash Flow₹3 Cr₹5 Cr₹6 Cr₹7 Cr₹3 Cr₹-10 Cr
Shareholding
Promoter 40.14% Institutions 0.02% Public 59.85%
About Lotus Eye Hospital & Institute Ltd.

Healthcare · Medical Care Facilities

Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India.

www.lotuseye.org
Efficiency & Working Capital
ROCE3%
Interest Coverage3.9
Dividend Payout
Debtor Days10 d
Inventory Days28 d
Payable Days25 d
Cash Conversion Cycle13 d
Working Capital Days38 d
Shareholding Details

As of 2026-06-30

Promoter40.1%
FII0%
DII0%
Institutions0%
Public59.8%
Promoter Pledge87.2%
No. of Shareholders9,627
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters57.6%56.6%41.4%40.2%40%40.1%40.2%40.4%40.6%40.7%40.1%40.1%
FIIs0%0%0%0%0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public42.4%43.4%58.6%59.8%59.9%59.8%59.7%59.6%59.3%59.3%59.8%59.8%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%87.2%87.2%
No. of Shareholders7,6608,31412,50211,75912,51411,73411,50811,12110,77710,2409,9399,627
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Sangeetha SShareholding of Promoter and Promoter Group35%72,74,272
Kovai Purani Finance Private LimitedPublic Shareholding7.9%16,49,578
Vramath Investment Consultancy Private LimitedPublic Shareholding4.8%10,06,744
Vramath Financial Services Private LimitedPublic Shareholding4.7%9,71,873
Rajiv ChoudharyPublic Shareholding4.5%9,42,005
Sangeeta ChoudharyPublic Shareholding3.9%8,15,000
Kavetha SundaramoorthyShareholding of Promoter and Promoter Group2.8%5,70,993
Thomas SantoshPublic Shareholding2.7%5,52,202
Late Kaliannagounder SundaramoorthyShareholding of Promoter and Promoter Group2.4%5,01,837
Mahendran DevikaPublic Shareholding2%4,09,522
K S RamalingamPublic Shareholding1.5%3,02,894
Urvija ChoudharyPublic Shareholding1.4%2,95,319
Madhavi Rubin ChhedaPublic Shareholding1.1%2,20,000
Sundaramoorthy RajkumarShareholding of Promoter and Promoter Group0%0
Asean Optics Private LimitedShareholding of Promoter and Promoter Group0%0
Eyeda Meds LlpShareholding of Promoter and Promoter Group0%0
Dr S K S Memorial Eye Hospitals Private LimitedShareholding of Promoter and Promoter Group0%0
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Sangeetha S72,74,272100%2026-06-30
Board of Directors
NameDesignationYear
Sangeetha SundaramoorthyED / MD / Promoter2025
Kaveetha SundaramoorthyChairman & Non Executive Dir.2025
K.S. RamalingamExecutive Director / Whole Time Director / CEO2025
S NatesanIndependent Non Exe. Director2025
Karthik VeeramaniIndependent Non Exe. Director2025
Perumalsamy MahendranIndependent Non Exe. Director2025
M Achuth menon,Company Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Healthcare activities₹0 Cr
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10252121
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000112
2025000000
2025000112
Insider / Designated-Person Trades

8 recent disclosure(s)

S RajkumarDisposal · 1,30,934
S RajkumarDisposal · 1,09,489
S RajkumarDisposal · 31,58,191
S RajkumarRevoke · 5,00,000
S RajkumarDisposal · 2,07,000
S RajkumarAcquisition · 19,664
Substantial Acquisitions (SAST)

4 disclosure(s)

Market02/02/2026 · 17,26,017
NULL03/02/2026 · 14,28,571
Market23/09/2025 · 12,000
-18/09/2025 · 11,42,900
Company Information
Incorporated1997
ChairmanKaveetha Sundaramoorthy
AuditorAnbarasu & Jalapathi
Investor Email[email protected]
🌐 www.lotuseye.org

📍 SF No770/12 Civil Aerodrome(P), Avinashi Road, Coimbatore, Tamil Nadu, 641014

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search